ChengDu ShengNuo Biotec Co.,Ltd.

Shanghai Stock Exchange 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd. Net Income Margin for the year ending December 31, 2023: 16.17%

ChengDu ShengNuo Biotec Co.,Ltd. Net Income Margin is 16.17% for the year ending December 31, 2023, a -0.78% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

ChengDu ShengNuo Biotec Co.,Ltd. Net Income Margin for the year ending December 31, 2022 was 16.30%, a 2.83% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Net Income Margin for the year ending December 31, 2021 was 15.85%, a 0.04% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Net Income Margin for the year ending December 31, 2020 was 15.84%, a 7.53% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Net Income Margin for the year ending December 31, 2019 was 14.73%, a 37.13% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Shanghai Stock Exchange: 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd.

CEO	Mr. Yongjun Wen
IPO Date	June 3, 2021
Location	China
Headquarters	258 Industrial Avenue Section
Employees	1,128
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company produces polypeptide APIs, tablets of solid preparation, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card type injections. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.

Key trends

Past 5 years